Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: Unexpected incidence of neurotoxicity

Gynecologic Oncology

Volumn 62, Issue 2, 1996, Pages 166-168

  Connelly, Elizabeth ^a   Markman, Maurie ^a   Kennedy, Alexander ^a   Webster, Kenneth ^a   Kulp, Barbara ^a   Peterson, Gertrude ^a   Belinson, Jerome ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; GRANISETRON; ONDANSETRON; PACLITAXEL;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HYPERSENSITIVITY; ENDOMETRIUM CANCER; FEMALE; GYNECOLOGIC CANCER; HUMAN; INFUSION; INTRAVENOUS DRUG ADMINISTRATION; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; VOMITING;

EID: 0030221119     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.0210     Document Type: Article

References (12)

1. 1. McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., and Davidson, M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer, N. Engl. J. Med. 334, 1-6 (1996).
2. 2. Rowinsky, E. K., and Donehower, R. C. Paclitaxel (Taxol), N. Engl. J. Med. 332, 1004-1014 (1995).
3. 3. Eisenhauer, E. A., ten Bokkel Huinink, W. W., Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E. L., Kerr, I., Vermerken, J. B., Buser, K., Colombo, N., Bacon, M., Santabarbara, P., Onetto, N., Winograd, B., and Canetta, R. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion, J. Clin. Oncol. 12, 2654-2666 (1994).
4. 4. Klastersky, J., and Sculier, J. P. Cisplatin plus taxol in non-small cell lung cancer: A dose finding trial, Proc. Am. Assoc. Cancer Res. 36, 239 (1995).
5. 5. Belli, L., Le Chevalier, T., Gottfried, M., Adams, D., Ruffle, P., Le Cesne, A., Tete, L., and Pallae-Cosset, B. Phase I-II trial of paclitaxel (Taxol) and cisplatin in previously untreated advanced non-small cell lung cancer (NSCLC), Proc. Am. Soc. Clin. Oncol. 14, 350 (1995).
6. 6. Gianni, L., Kearns, C. M., Giani, A., Capri, G., Vigano, L., Locatelli, A., Bonadonna, G., and Egorin, M. J. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans, J. Clin. Oncol. 13, 180-190 (1995).
7. 7. Ohtsu, T., Sasaki, Y., Tamura, T., Miyata, Y., Nakanomyo, H., Nishiwaki, Y., and Saijo, N. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: A 3-hour infusion versus a 24-hour infusion, Clin. Cancer Res. 1, 599-606 (1995).
8. 8. Sarosy, G., Kohn, E., Stone, D. A., Rothenberg, M., Jacob, J., Adamo, D. O., Ognibene, F. P., Cunnion, R. E., and Reed, E. Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer, J. Clin. Oncol. 10, 1165-1170 (1992).
9. 9. Rowinsky, E. K., Chaudhry, V., Forastiere, A. A., Sartorius, S. E., Ettinger, D. S., Grochow, L. B., Lubejko, B. G., Cornblath, D. R., and Donehower, R. C. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting, J. Clin. Oncol. 11, 2010-2020 (1993).
10. 10. Chaudhry, V., Rowinsky, E. K., Sartorius, S. E., Donehower, R. C., and Cornblath, D. R. Peripheral neuropathy from Taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies, Ann. Neurol. 35, 304-311 (1994).
11. 11. Warner, E. Neurotoxicity of cisplatin and Taxol, Int. J. Gynecol. Cancer 5, 161-169 (1995).
12. 12. Calvert, A. H., Boddy, A., Bailey, N. P., Siddiqui, N., Humphreys, A., Hughes, A., Robson, L., Gumbrell, L., Thomas, H., Chapman, F., Proctor, M., Simmons, D., Oakey, A., Lind, M. J., Sinha, D. V., and Newell, D. R. Carboplatin in combination with paclitaxel in advanced ovarian cancer: Dose determination and pharmacokinetic and pharmacodynamic interactions, Semin. Oncol. 22(Suppl. 12), 91-98 (1995).